

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CK Life Sciences Int'l. (Holdings) Inc.**

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

**UPDATE ON DIRECTOR'S INFORMATION  
PURSUANT TO RULES 13.51(2)(I) AND 13.51B(2)  
OF THE LISTING RULES**

This announcement is made by CK Life Sciences Int'l., (Holdings) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.51(2)(I) and Rule 13.51B(2) of the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to an update of information of Mr. Kwan Kai Cheong (“**Mr. Kwan**”), an independent non-executive director of the Company.

The board of directors (the “**Board**”) of the Company was notified by Mr. Kwan that it had recently come to his attention that on 31 May 2023, an order was granted by the High Court of Hong Kong for the winding up of China Properties Group Limited (“**China Properties**”) (a company of which Mr. Kwan was a non-executive director) (the “**Winding-up Order**”) and the Official Receiver was appointed as the provisional liquidator of China Properties. Mr. Kwan was appointed as a non-executive director of China Properties on 1 February 2007.

China Properties is a company incorporated in the Cayman Islands with limited liability whose shares are listed on the Main Board of the Stock Exchange (stock code: 1838). Based on the information issued by China Properties, the principal businesses of China Properties and its subsidiaries are property development and property investment in the People's Republic of China. Neither China Properties nor any of its subsidiaries is related to the Group. For further information in relation to the Winding-up Order, please refer to the announcements of China Properties published on the website of the Stock Exchange.

The Board is of the view that the Winding-up Order does not and will not have any impact on the business and operations of the Group, nor does it affect Mr. Kwan's suitability in fulfilling his duties as an independent non-executive director of the Company.

Mr. Kwan has confirmed that save as disclosed in this announcement, there is no other matter which is required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules, and he is not aware of any other matter that needs to be brought to the attention of the Company and its shareholders.

By Order of the Board  
**CK Life Sciences Int'l., (Holdings) Inc.**  
**Eirene Yeung**  
*Company Secretary*

Hong Kong, 7 June 2023

*As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director), Mr. Paul Joseph Tighe (Independent Non-executive Director) and Mr. Donald Jeffrey Roberts (Independent Non-executive Director).*